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Abstract
Background: The administration of an extra dose of a vaccine may occur due to a programmatic 
error (e.g., vaccination error) when there is need to provide one of the antigens of a combination 
vaccine not readily available as a single antigen, or when there is need to provide immunization in 
a person with uncertain vaccination histories (e.g., refugees). There is little data available on the 
safety of an extra dose of vaccine.
Objective: To assess for the presence of adverse events (AEs) most commonly reported 
following the administration of excess doses of vaccine in the Vaccine Adverse Event Reporting 
System (VAERS).
Methods: We searched VAERS for US reports where an excess dose of vaccine was administered 
to a person received from 1/1/2007 through 1/26/2018. We reviewed medical records for all 
serious reports and a random sample of non-serious reports. The most common AEs among 
reports of excess dose of vaccine administered were compared with the corresponding AEs for all 
vaccines reported to VAERS during the same period.
Results: Out of 366,815 total VAERS reports received, 5067 (1.4%) reported an excess dose of 
vaccine was administered; 3898 (76.9%) did not describe an adverse health event (AHE). The 
most common vaccines reported were trivalent inactivated influenza (15.4%), varicella (13.9%), 
hepatitis A (11.4%), and measles, mumps, rubella, varicella (11.1%). Among reports where only 
AHEs were reported, the most common were pyrexia (12.8%), injection site erythema (9.7%), 
injection site pain (8.9%), and headache (6.6%). The percentage of AHEs among these reports was 
comparable to all reports submitted to VAERS during the same study period.
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Conclusion: More than three-fourths of reports of an excess dose of vaccine did not describe an 
AHE. Among reports where an AHE event was reported, we did not observe any unexpected 
conditions or clustering of AEs.
Keywords
Adverse event; Epidemiology; Excess dose; Extra dose; Surveillance; Vaccination errors; Vaccine 
safety
1. Introduction
Administration of an excess dose of a vaccine can occur under several scenarios: (1) 
administration of an excess dose of the same antigen due to a vaccination error (e.g., 
healthcare provider, documentation, or patient recall errors); (2) in the context of 
combination vaccines, such as when there is need to provide one of the antigens not readily 
available as a single antigen; (3) when there is a need to provide immunizations to 
individuals with uncertain vaccination histories, as in the case of special populations (e.g, 
refugees with missing records and unknown immune status). The Advisory Committee on 
Immunization Practices (ACIP) has specific recommendations regarding the administration 
of excess doses of vaccine [1] indicating that administration of excess antigens contained in 
a combination vaccine should be avoided in most situations. However, this may be justified 
if the excess antigen is not contraindicated, if the potential benefits to the patient outweigh 
the potential risk for adverse events (AEs) associated with the excess antigens, if the 
products that contain only the needed antigens are not readily available, and if there is better 
overall economic value if the direct and indirect costs of excess injections are taken into 
consideration. The ACIP recommendations state that an excess dose of many live-virus 
vaccines and Haemophilus influenzae or hepatitis B vaccine has not been found to be 
harmful [2,3], but the risk for an AE might increase when excess doses are administered at 
an earlier time than the recommended interval for certain vaccines [e.g., tetanus toxoid 
vaccines and pneumococcal polysaccharide vaccine (23-valent)] [4–8]. In some 
circumstances, the provider might prefer to use a combination vaccine to reduce the required 
number of injections. In such cases, the benefits and risks of administering the combination 
vaccine with an unneeded antigen should be carefully considered and discussed with the 
patient or parent. For most other vaccines in the immunization schedule, there is little if any 
information on AEs resulting from their excessive administration.
The objective of this study is to describe the characteristics of AEs associated with reports in 
VAERS where an excess dose of vaccine was administered.
2. Material & methods
2.1. VAERS
VAERS is a US national passive vaccine safety surveillance system created in 1990 and co-
administered by the Centers for Disease Control and Prevention (CDC) and the Food and 
Drug Administration (FDA). It receives reports of AEs following vaccination but may also 
receive reports of vaccination errors not describing an AE [9]. VAERS accepts reports from 
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vaccine manufacturers, healthcare providers, vaccine recipients and others. The VAERS 
report form collects information on age, sex, vaccines administered, dose and lot number, 
the AE experienced, and health history. Signs and symptoms of AEs are coded by trained 
personnel using the Medical Dictionary for Regulatory Activities (MedDRA), a clinically 
validated, internationally standardized terminology [10]. A VAERS report may be assigned 
one or more MedDRA preferred terms (PTs). A PT is a distinct descriptor for a symptom, 
sign, disease, diagnosis, therapeutic indication, investigation, medical error, surgical, or 
medical procedure, or medical, social, or family history characteristic [10], but PTs are not 
necessarily medically confirmed diagnoses. System Organ Class (SOC) is the highest level 
of the MedDRA hierarchy that provides the broadest classification for AEs (e.g., nervous 
system disorders) [11]. Reports are classified as serious or non-serious based on the Code of 
Federal Regulations (21-CFR) if one or more of the following are reported: death, life-
threatening illness, hospitalization or prolongation of existing hospitalization, permanent 
disability, or a congenital anomaly/birth defect [12]. For serious reports, medical records are 
routinely requested and made available to VAERS personnel. Vaccine manufacturers are 
responsible for following up on serious reports or unexpected AEs submitted to them [9].
2.1.1. Search of reports—We searched the VAERS database for reports received for 
the analytic period January 1, 2007 through January 26, 2018 for: (1) reports containing any 
of the following MedDRA PTs: accidental overdose, extra dose administered, incorrect dose 
administered, multiple drug overdose, overdose, incorrect dosage administered and (2) 
reports containing the text string “extra dose” “excess dose” “overdose” or “additional dose” 
in the symptom, pre-existing and medical history variables. Excess dose of a vaccine was 
defined as greater than recommended volume, quantity, or dosage of a vaccine which may 
have been given on the same date or on separate dates. For example, a report of two doses of 
inactivated influenza vaccine for an adult patient on the same date or during the same 
influenza season were considered as excess doses. Pregnancy reports were searched using 
methods previously described [21].
2.1.2. Analysis of reports—We conducted descriptive analyses of reports by age, sex, 
vaccines administered, vaccines given in excess, type of administration error or reason for 
the excess dose, and the most common MedDRA PTs among reports where an adverse 
health event was described.
2.1.3. Clinical review—Investigators from CDC (PLM, JA) reviewed all serious reports 
and a simple random sample of non-serious reports and any available medical records to 
characterize AEs, if any. This review also sought to understand the circumstances under 
which an excess dose of vaccine was administered to identify opportunities for prevention. 
The main AE or diagnosis was classified using the MedDRA SOC [10]. Reports determined 
to be not related to an excess dose of a vaccine (e.g., overdose of a non-vaccine medication) 
were excluded.
Because VAERS is a routine, government-sponsored surveillance system that does not meet 
the definition of research, this investigation was not subject to institutional review board 
review or informed consent requirements.
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3. Results
During the analytic period of this review, 366,815 total reports were submitted to VAERS. 
We detected 5067 reports of excess doses of vaccine administered. The proportions of 
reports of excess dose received increased from 0.8% in 2007 to a peak of 2.4% in 2015. The 
vaccine type most commonly associated with these reports (which also peaked during 2015) 
were inactivated influenza vaccines. Of the 5067 reports, 3898 (76.9%) did not describe an 
AE or any sign or symptom (Table 1). The most common reporters were vaccine 
manufacturers (3,168;62.5%). The most common vaccines reported were trivalent 
inactivated influenza, varicella, hepatitis A vaccines, and measles, mumps, rubella, varicella, 
vaccines (Table 2). The most frequent MedDRA PTs for all reports of excess dose of vaccine 
where an adverse health event was reported were systemic (e.g., fever) or local injection site 
reactions (Table 3).
3.1. Serious and non-serious reports
Clinical review of all available records for the 158 serious reports identified through the 
initial automated search strategy determined that 64 were cases involving an excess vaccine 
dose. Some of the false positives included reports with MedDRA PTs for incorrect dose 
administered, but not an excess dose when reviewed. Other false positives included 
MedDRA PTs for multiple drug overdose where a drug but not a vaccine was administered 
in excess. The SOCs most commonly reported among these excess dose serious reports were 
general disorders and administration site conditions (17), nervous system disorders (7), and 
immune system disorders (4) [ Table 4a]. The most common vaccines given in excess among 
these serious reports were pneumococcal polysaccharide (13), influenza (10), hepatitis B (9), 
human papillomavirus (6) and herpes zoster (5). No specific pattern or cluster of AEs (e.g., 
injection site reactions) was found to occur with any of these vaccines given in excess.
We also reviewed a 6% random sample of non-serious reports (n = 279) (Table 4b). Most of 
these non-serious reports (245;87.8%) did not describe an adverse health event. The most 
common vaccines for those reports with adverse health events (n = 34) were influenza (9), 
human papillomavirus (9), Pneumococcal polysaccharide vaccine (5), DTaP (5), herpes 
zoster (3), hepatitis A (2), hepatitis B (1). No cluster of AEs was observed for any of these 
vaccines. All reports were vaccination errors and the person giving the vaccine was not 
aware an excess dose of vaccine was being given. Most reports (~90%) did not describe the 
circumstances that led to administration of an excess dose of vaccine. However, in some 
reports the provider did not review the vaccination records; in other cases the patient did not 
recall having received the vaccine previously (e.g., influenza vaccine), and in other cases a 
child received an adult dose of the vaccine. In 127 (45.5%) of 279 non-serious reports an 
additional dose of vaccine was given on the same day. In 149 (53.4%), the excess dose of 
vaccine was given on a different date. In 10 reports, an adult vaccine formulation was given 
incorrectly to a child.
Among 1169 reports of an excess dose of vaccine with an adverse health event, the 10 most 
common PTs were for local or systemic reactions and were comparable to the respective PTs 
in the entire VAERS database (Table 5).
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3.2. Excess vaccine doses among pregnancy reports
We identified and reviewed 51 reports where an excess dose of a vaccine was given to a 
pregnant woman. Vaccines given in excess were inactivated influenza vaccine (33), Tdap (9), 
hepatitis B (1), human papilloma virus vaccine (6), and MMRII (2). In the latter two, the 
provider did not know the woman was pregnant. Most (38; 74.5%) reports did not describe 
an adverse health event. Among the 13 reports with an AE, some of the diagnoses included 
injection site reaction/arm soreness (10), scabies (1), headache/dysuria (1), and Taussig-Bing 
anomaly-infant-birth defect in a woman vaccinated with Tdap in the third trimester (1).
4. Discussion
This review of the VAERS database demonstrated that excess doses of vaccine were reported 
in 1.4% of all VAERS reports submitted during January 1, 2007 through January 26, 2018. 
The number of reports has been increasing over time and this increase parallels the general 
increase of most vaccination error reports in VAERS [14]. We noted that these reports 
occurred due to diverse vaccination errors, typically programmatic errors many of which 
should have been avoided by greater awareness of the administration instructions for the 
vaccines being administered or increased awareness of the immunization history of the 
patient.
There is some evidence that suggests there may be an increased risk of local reactions with 
repeated doses of certain vaccines such as DTaP. In pre-licensure studies of DTaP, large 
injection site reactions were observed to occur more frequently after the fifth dose of DTaP 
than after the previous four doses [15]. Similarly, for children vaccinated with a fourth dose 
of DTaP, which was the same DTaP received in the primary series, fever and injection site 
redness, swelling, and pain increased in prevalence compared with the third dose in the 
primary series [16]. The findings of this review seem reassuring since no adverse health 
events were reported in three-fourth of reports and among reports where an adverse health 
event was reported, injection site and systemic reactions were the most common conditions 
reported.
Some studies have shown an increased risk of AEs when tetanus-containing vaccines are 
given at short intervals. A clinical trial of 7156 children found that Tdap vaccine was well 
tolerated when given at intervals as short as 18 months from the prior tetanus-containing 
vaccine. However, the authors noted an increased risk of solicited reports of injection site 
swelling and erythema in children who received a tetanus-toxoid-containing vaccine more 
recently [17]. A retrospective cohort study of 436,828 Td vaccinations in the Vaccine Safety 
Datalink (VSD) found that medically attended local reactions, including cellulitis, were 
more common among persons who received a Td-containing vaccine within the preceding 5 
years compared with a longer interval [18]. Another study of 4524 health-care workers 
vaccinated with Tdap during a pertussis outbreak in New England found that there was no 
difference in the rates of solicited moderate or severe injection site reactions, but there was 
an increase in redness, swelling, and subjective fever among patients who had received their 
prior Td-containing vaccine less than 2 years earlier [19].
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An increased risk of AEs when administering tetanus-toxoid-containing vaccines within a 
short interval has been an area of concern now that ACIP recommends a dose of Tdap 
vaccine during every pregnancy irrespective of prior vaccination with a tetanus-toxoid-
containing vaccine [20]. However, a recent study in the VSD found that among women who 
received Tdap vaccination during pregnancy, there was no increased risk of acute AEs or 
adverse birth outcomes for those who had been previously vaccinated within 2 years or 2–5 
years compared with those who had been vaccinated more than 5 years prior [21].
In our review, we included pregnant women who had received a dose of vaccine in excess. 
Upon review of these pregnancy reports, we found that only a quarter of reports described an 
AE. The vaccines most commonly associated with these pregnancy reports were influenza or 
Tdap vaccines which are the two vaccines recommended for administration specifically 
during pregnancy. A previous review of maternal Tdap safety reports in VAERS described 
the nature of the vaccination errors where an excess dose of Tdap vaccine was given to a 
pregnant woman [13].
There are few other studies evaluating the safety of excess doses of any given vaccine. One 
recent report documented the administration of a five-fold higher dose of yellow fever 
vaccine to each of four persons in a military clinic [22]. Only one reported symptoms, which 
included abdominal pain and arm pain and which resolved following supportive intravenous 
fluid treatment. Three other studies in Brazil documented administration of a 10 to 25-fold 
overdose of 17-DD yellow fever vaccine among 64 individuals; only one person was 
hospitalized (for possible acute vis-cerotropism and eventually recovered) [23–25].
VAERS is the frontline surveillance system used to monitor the post-licensure safety of US 
vaccines. Strengths of VAERS include its broad national scope and timeliness [9]. VAERS 
can rapidly detect unexpected patterns and rare AEs that might represent potential safety 
signals that can be further evaluated in more robust data systems using population-based 
studies. VAERS is subject to the inherent limitations of passive surveillance system. Some of 
these limitations include over- or under-reporting, reporting biases, inconsistency in quality 
and completeness of reports, lack of denominator information, and lack of an unvaccinated 
comparison group [9]. For example, 63% of reports were submitted by vaccine 
manufacturers who are required by law to report to VAERS and this may introduce bias. Due 
to these limitations, we generally cannot assess if a vaccine caused an AE from VAERS data 
alone.
5. Conclusion
In this safety assessment of reports submitted to VAERS with excess doses of vaccine 
administered, we did not identify any new or unexpected safety issues. In some 
circumstances, querying patients about vaccination history especially with influenza vaccine, 
better awareness of specific vaccine recommendations, improved documentation in the 
medical record, and timely access to vaccination histories, may help prevent administration 
of excess doses of vaccines.
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Table 1
Characteristics of recipients of excess doses of vaccine reported to VAERS, January 2007—July 2017.
Characteristic
Median age (range), years 11(0–98)
No (%)
Number of reports 5067
Serious 158 (3.1)
Reports with no adverse health event 3898 (76.9)
Female sex 1849 (36.5)
Male sex 1426 (28.1)
Unknown sex 1792 (35.4)
Age groupsa
0–11 months 438 (8.6)
1–6 years 1089 (21.5)
7–18 years 731 (14.4)
19–64 years 808 (16.0)
≥65 years 379 (7.5)
Type of reporter
Manufacturer 3168 (62.5)
Provider 1180 (23.3)
Other 619 (12.2)
Parent/patient 100 (2.0)
aAge unknown in 1622 (32%).
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Table 2
Most common vaccines administered in excess reported to VAERS, January 2007—July 2017 (N = 5067)†.
Vaccine N (%)
Trivalent inactivated influenza 778 (15.4)
Varicella 706 (13.9)
Hepatitis A 579 (11.4)
Measles, mumps, rubella, varicella 561 (11.1)
Varicella zoster 545 (10.8)
Hepatitis B 519 (10.2)
Quadrivalent human papilloma virus 374 (7.4)
Measles, mumps, rubella 359 (7.1)
Pneumococcal polysaccharide vaccine (23-valent) 299 (5.9)
Pneumococcal conjugate vaccine (13-valent) 280 (5.5)
Haemophilus influenzae type b conjugate vaccine 267 (5.3)
TdaP 226 (4.4)
DTaP 214 (4.2)
Quadrivalent inactivated influenza 191 (3.8)
DTaPHep B-IPV 189 (3.7)
Quadrivalent meningococcal conjugate vaccine 183 (3.6)
Inactivated polio vaccine 175 (3.4)
Ninevalent human papilloma virus 168 (3.3)
Rotavirus vaccine (pentavalent) 160 (3.2)
DTaP: Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed.
Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed.
DTaPHep B-IPV: Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B and inactivated poliovirus vaccine.
†
Reports may not be mutually exclusive.
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Table 3
Adverse health events among reports where an excess dose of vaccine was administered, VAERS, January 
2007–July 2017† (n = 1169).
Adverse health events N (%)
Pyrexia 150 (12.8)
Injection site erythema 113 (9.7)
Injection site pain 104 (8.9)
Headache 77 (6.6)
Injection site swelling 76 (6.5)
Pain in extremity 75 (6.4)
Pain 69 (5.9)
Vomiting 61 (5.2)
Nausea 52 (4.4)
Dizziness 51 (4.4)
Fatigue 50 (4.3)
Cough 46 (3.9)
†
Reports may not be mutually exclusive.
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Table 4
Adverse events among serious reports and a random sample of non-serious reports of excess doses of vaccine 
reported to VAERS, January 1, 2007–July 2017.
4a. Serious reports after clinical review
Adverse event (System Organ Class) N (%)
General disorders and administration site conditions 17 (26.6)
Nervous system disorders 7 (10.9)
Immune system disorders 4 (6.3)
Infections and infestations 6 (9.4)
Psychiatric disorders 6 (9.4)
Metabolism and nutrition disorders 3 (4.7)
Gastrointestinal disorders 3 (4.7)
Cardiac disorders 3 (4.7)
Deathsa 4 (6.3)
No adverse health event reportedb 4 (6.3)
Otherc 7 (10.9)
Total 64
4b. Random sample of non-serious reports
General disorders and administration site conditions 14 (5.0)
Nervous system disorders 7 (2.5)
Immune system disorders 6 (2.2)
Infections and infestations 2 (0.7)
Respiratory, thoracic and mediastinal disorders 2 (0.7)
Gastrointestinal disorders 1 (0.4)
Blood and lymphatic system disorders 1 (0.4)
Reproductive system and breast disorders 1 (0.4)
No adverse health event reported 245 (87.8)
Total 279
aCauses of death include: end-stage congestive heart failure, thrombosis, Sudden infant death syndrome and unknown cause.
b
Report indicated patient was hospitalzed but did not report an adverse health event.
c
The other includes two reports of an unspecified adverse event and one report each of injury, poisoning and procedural complications, blood and 
lymphatic system disorders, musculoskeletal and connective tissue disorders, respiratory, thoracic and mediastinal disorders, and vascular disorders.
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Table 5
MedDRAa preferred terms most commonly reported among reports where an excess dose of vaccine was 
administered compared to the rest of the VAERS database, January 2007–July 2017b.
MedDRA PT Excess dose VAERS database
N = 1,169 N = 301,805
N (%) N (%)
Pyrexia 150 (12.8) 44,574 (14.8)
Injection site erythema 113 (9.7) 48,767 (16.2)
Injection site pain 104 (8.9) 33,183 (11.0)
Headache 77 (6.6) 24,455 (8.1)
Injection site swelling 76 (6.5) 36,419 (12.1)
Pain in extremity 75 (6.4) 24,375 (8.1)
Pain 69 (5.9) 29,143 (9.7)
Vomiting 61 (5.2) 16,824 (5.6)
Nausea 52 (4.4) 18,997 (6.3)
Dizziness 51 (4.4) 19,221 (6.4)
Fatigue 50 (4.3) 14,836 (4.9)
Cough 46 (3.9) 9487 (3.1)
Irritability 46 (3.9) 5707 (1.9)
Erythema 43 (3.7) 30,811 (10.2)
Rash 43 (3.7) 22,044 (7.3)
a
MedDRA: Medical Dictionary for Regulatory Activities.
b
Reports with no adverse health events reported were excluded.
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